{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:52:55Z","timestamp":1781823175915,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Natural Science Foundation Program","award":["82272320"],"award-info":[{"award-number":["82272320"]}]},{"name":"High-level Health Talent Construction Project","award":["Discipline leader-02-11"],"award-info":[{"award-number":["Discipline leader-02-11"]}]},{"name":"Gilead Sciences","award":["IN-US-380-7643"],"award-info":[{"award-number":["IN-US-380-7643"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-026-09749-6","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T07:03:52Z","timestamp":1777619032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bictegravir\/emtricitabine\/tenofovir alafenamide versus dolutegravir plus lamivudine plus tenofovir disoproxil fumarate in people living with HIV experiencing virologic failure in China: a study protocol for a multicenter, open-label, randomized controlled non-inferiority trial"],"prefix":"10.1186","volume":"27","author":[{"given":"Ran","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"9749_CR1","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/hiv.13542","volume":"24","author":"J Ambrosioni","year":"2023","unstructured":"Ambrosioni J, Levi L, Alagaratnam J, Van Bremen K, Mastrangelo A, Waalewijn H, et al. Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023. HIV Med. 2023;24:1126\u201336. https:\/\/doi.org\/10.1111\/hiv.13542.","journal-title":"HIV Med"},{"key":"9749_CR2","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV. Department of Health and Human Services. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv. Accessed 24 Apr 2025. Cited 2025 Apr 24."},{"key":"9749_CR3","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1097\/CM9.0000000000003383","volume":"137","author":"Acquired Immunodeficiency Syndrome Professional Group, Society of Infectious Diseases, Chinese Medical Association","year":"2024","unstructured":"Acquired Immunodeficiency Syndrome Professional Group, Society of Infectious Diseases, Chinese Medical Association, Chinese Center for Disease Control and Prevention. Chinese guidelines for the diagnosis and treatment of human immunodeficiency virus infection\/acquired immunodeficiency syndrome (2024 edition). Chin Med J (Engl). 2024;137:2654\u201380. https:\/\/doi.org\/10.1097\/CM9.0000000000003383.","journal-title":"Chin Med J (Engl)"},{"key":"9749_CR4","doi-asserted-by":"publisher","first-page":"5334","DOI":"10.1038\/s41467-023-41051-w","volume":"14","author":"X Wu","year":"2023","unstructured":"Wu X, Wu G, Ma P, Wang R, Li L, Chen Y, et al. Associations of modern initial antiretroviral therapy regimens with all-cause mortality in people living with HIV in resource-limited settings: a retrospective multicenter cohort study in China. Nat Commun. 2023;14:5334. https:\/\/doi.org\/10.1038\/s41467-023-41051-w.","journal-title":"Nat Commun"},{"key":"9749_CR5","doi-asserted-by":"publisher","first-page":"664","DOI":"10.46234\/ccdcw2023.129","volume":"5","author":"X Liu","year":"2023","unstructured":"Liu X, Wang D, Hu J, Song C, Liao L, Feng Y, et al. Changes in HIV-1 subtypes\/sub-subtypes, and transmitted drug resistance among ART-na\u00efve HIV-infected individuals - China, 2004-2022. China CDC Wkly. 2023;5:664\u201371. https:\/\/doi.org\/10.46234\/ccdcw2023.129.","journal-title":"China CDC Wkly"},{"key":"9749_CR6","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1093\/jac\/dkac338","volume":"77","author":"AJ Ntamatungiro","year":"2022","unstructured":"Ntamatungiro AJ, Kagura J, Weisser M, Francis JM. Pre-treatment HIV-1 drug resistance in antiretroviral therapy-naive adults in Eastern Africa: a systematic review and meta-analysis. J Antimicrob Chemother. 2022;77:3231\u201341. https:\/\/doi.org\/10.1093\/jac\/dkac338.","journal-title":"J Antimicrob Chemother"},{"key":"9749_CR7","doi-asserted-by":"publisher","first-page":"1179568","DOI":"10.3389\/fpubh.2023.1179568","volume":"11","author":"Y Xu","year":"2023","unstructured":"Xu Y, Shi H, Dong X, Ding C, Wu S, Li X, et al. Transmitted drug resistance and transmission clusters among ART-na\u00efve HIV-1-infected individuals from 2019 to 2021 in Nanjing, China. Front Public Health. 2023;11:1179568. https:\/\/doi.org\/10.3389\/fpubh.2023.1179568.","journal-title":"Front Public Health"},{"key":"9749_CR8","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3760\/cma.j.issn.0253-9624.2017.11.007","volume":"51","author":"PP Xiao","year":"2017","unstructured":"Xiao PP, Lu J, Hu HY, Xu XQ, Ding P, Fu GF, et al. Drug resistance mutations and its associated factors among 579 HIV\/AIDS patients experiencing failure of antiretroviral therapy in Jiangsu Province, China. Zhong hua Yu Fang Yi Xue Za Zhi. 2017;51:988\u201393. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-9624.2017.11.007.","journal-title":"Zhong hua Yu Fang Yi Xue Za Zhi"},{"key":"9749_CR9","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/jac\/dkab430","volume":"77","author":"L Yan","year":"2022","unstructured":"Yan L, Yu F, Liang J, Cheng Y, Li H, Zhao Q, et al. Drug resistance profiles and influencing factors among HIV-infected children and adolescents receiving long-term ART: a multicentre observational study in China. J Antimicrob Chemother. 2022;77:727\u201334. https:\/\/doi.org\/10.1093\/jac\/dkab430.","journal-title":"J Antimicrob Chemother"},{"key":"9749_CR10","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.2147\/IDR.S317187","volume":"14","author":"Y Lan","year":"2021","unstructured":"Lan Y, Deng X, Li L, Cai W, Li J, Cai X, et al. HIV-1 drug resistance and genetic transmission networks among MSM failing antiretroviral therapy in South China 2014-2019. Infect Drug Resist. 2021;14:2977\u201389. https:\/\/doi.org\/10.2147\/IDR.S317187.","journal-title":"Infect Drug Resist"},{"key":"9749_CR11","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa2101609","volume":"385","author":"NI Paton","year":"2021","unstructured":"Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, et al. Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV. N Engl J Med. 2021;385:330\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2101609.","journal-title":"N Engl J Med"},{"key":"9749_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","volume":"19","author":"M Aboud","year":"2019","unstructured":"Aboud M, Kaplan R, Lombaard J, Zhang F, Hidalgo JA, Mamedova E, et al. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Lancet Infect Dis. 2019;19:253\u201364. https:\/\/doi.org\/10.1016\/S1473-3099(19)30036-2.","journal-title":"Lancet Infect Dis"},{"key":"9749_CR13","doi-asserted-by":"publisher","first-page":"e381","DOI":"10.1016\/S2352-3018(22)00092-3","volume":"9","author":"NI Paton","year":"2022","unstructured":"Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, et al. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. Lancet HIV. 2022;9:e381\u201393. https:\/\/doi.org\/10.1016\/S2352-3018(22)00092-3.","journal-title":"Lancet HIV"},{"key":"9749_CR14","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1093\/jac\/dkae138","volume":"79","author":"I Chivite","year":"2024","unstructured":"Chivite I, Berrocal L, de Lazzari E, Navadeh S, Lluis-Ganella C, Inciarte A, et al. Effectiveness, safety and discontinuation rates of bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) in people with HIV using real-world data: a systematic review and meta-analysis. J Antimicrob Chemother. 2024;79:1775\u201383. https:\/\/doi.org\/10.1093\/jac\/dkae138.","journal-title":"J Antimicrob Chemother"},{"key":"9749_CR15","doi-asserted-by":"publisher","unstructured":"P\u00e9rez-Valero I, Mata DC, Espejo AC, Gallo M, de Morales AGG-R, Fanciulli C, et al. Real-world effectiveness and safety of BIC\/FTC\/TAF in comparison with other regimens in people with HIV starting therapy with AIDS-defining conditions. Results from the CORIS Cohort: The ACTUAS II Study. Clin Infect Dis. 2025;ciaf162. https:\/\/doi.org\/10.1093\/cid\/ciaf162","DOI":"10.1093\/cid\/ciaf162"},{"key":"9749_CR16","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1093\/jac\/dkz347","volume":"74","author":"K Andreatta","year":"2019","unstructured":"Andreatta K, Willkom M, Martin R, Chang S, Wei L, Liu H, et al. Switching to bictegravir\/emtricitabine\/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V\/I. J Antimicrob Chemother. 2019;74:3555\u201364. https:\/\/doi.org\/10.1093\/jac\/dkz347.","journal-title":"J Antimicrob Chemother"},{"key":"9749_CR17","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.2147\/IDR.S331647","volume":"14","author":"H-M Chang","year":"2021","unstructured":"Chang H-M, Chou P-Y, Chou C-H, Tsai H-C. Outcomes after switching to BIC\/FTC\/TAF in patients with virological failure to protease inhibitors or non-nucleoside reverse transcriptase inhibitors: a real-world cohort study. Infect Drug Resist. 2021;14:4877\u201386. https:\/\/doi.org\/10.2147\/IDR.S331647.","journal-title":"Infect Drug Resist"},{"key":"9749_CR18","unstructured":"Pierre S, Bernard MJ, Homeus F, Bernadin GR. Switching from a second-line boosted PI regimen to B\/F\/TAF: Results of a randomized clinical trial. In: Conference on Retroviruses and Opportunistic Infections (CROI). Abstract #00641. Poster presentation. Denver, CO, USA; 2024. https:\/\/www.natap.org\/2024\/CROI\/croi_181.htm. Accessed 7 May 2025. Cited 2025 May 7."},{"key":"9749_CR19","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12955-019-1208-8","volume":"17","author":"MJ Fuster-RuizdeApodaca","year":"2019","unstructured":"Fuster-RuizdeApodaca MJ, Lagu\u00eda A, Safreed-Harmon K, Lazarus JV, Cenoz S, Del Amo J. Assessing quality of life in people with HIV in Spain: psychometric testing of the Spanish version of WHOQOL-HIV-BREF. Health Qual Life Outcomes. 2019;17:144. https:\/\/doi.org\/10.1186\/s12955-019-1208-8.","journal-title":"Health Qual Life Outcomes"},{"key":"9749_CR20","doi-asserted-by":"publisher","first-page":"e016382","DOI":"10.1136\/bmjopen-2017-016382","volume":"7","author":"Y Zhu","year":"2017","unstructured":"Zhu Y, Liu J, Qu B. Psychometric properties of the Chinese version of the WHOQOL-HIV BREF to assess quality of life among people living with HIV\/AIDS: a cross-sectional study. BMJ Open. 2017;7:e016382. https:\/\/doi.org\/10.1136\/bmjopen-2017-016382.","journal-title":"BMJ Open"},{"key":"9749_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","volume":"28","author":"DJ Buysse","year":"1989","unstructured":"Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193\u2013213. https:\/\/doi.org\/10.1016\/0165-1781(89)90047-4.","journal-title":"Psychiatry Res"},{"key":"9749_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361\u201370. https:\/\/doi.org\/10.1111\/j.1600-0447.1983.tb09716.x.","journal-title":"Acta Psychiatr Scand"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09749-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09749-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09749-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:20:21Z","timestamp":1781821221000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09749-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9749"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09749-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the Ethics Committee of Beijing Youan Hospital, Capital Medical University (Approval No. Jing-You-Ke-Lun Zi [2025]053). Written informed consent will be obtained from all participants prior to enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {30}"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {7b}"}}],"article-number":"449"}}